Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Covering: 2000 to 2019 According to a 2012 survey from the Centers for Disease Control
and Prevention, approximately 18% of the US population uses natural products (including …

Combinatorial therapies have been recently proposed to improve the efficacy of anticancer
treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug …

Ferroptosis is a form of regulated cell death that emerges to be relevant for therapy-resistant
and dedifferentiating cancers. Although several lines of evidence suggest that ferroptosis is …

The tumor accumulation of nanomedicines relies on the enhanced permeability and
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …

Pancreatic ductal adenocarcinoma (PDA) was responsible for~ 44,000 deaths in the United
States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically …

Genetic and epigenetic changes in DNA are involved in cancer development and tumor
progression. Histone deacetylases (HDACs) are key regulators of gene expression that act …

Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it
can only extend limited survival. It is imperative to find a combination strategy to increase …

Implant-related infections are serious complications after bone surgery and can compromise
the intended functions of artificial implants, leading to surgical failure and even amputation …

Abstract Glutathione peroxidase 4 (GPX4) is a regulator of ferroptosis (iron-dependent, non-
apoptotic cell death); its inhibition can render therapy-resistant cancer cells susceptible to …